Intellia Therapeutics

Research only

NTLA · Tracked drugs and regulatory events

Tracked programs

1 program

hereditary angioedema

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sec-filingir.intelliatx.com

Sponsor filing describes an in vivo CRISPR therapy and a March 10, 2027 FDA target.

Sponsor clinical-trials page links HAELO to NCT06634420.

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.